Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study

Background: The increasing use of immune checkpoint inhibitors (ICIs) in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of cardiovascular (CV) immune-related adverse events (irAEs). The current follow-up guidelines are...

Descripción completa

Detalles Bibliográficos
Autores principales: Delombaerde, Danielle, De Sutter, Johan, Croes, Lieselot, Vervloet, Delphine, Moerman, Veronique, Van de Veire, Nico, Willems, Anne-Marie, Wouters, Kristien, Peeters, Marc, Prenen, Hans, Vulsteke, Christof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142365/
https://www.ncbi.nlm.nih.gov/pubmed/37111382
http://dx.doi.org/10.3390/ph16040625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142365/
https://www.ncbi.nlm.nih.gov/pubmed/37111382
http://dx.doi.org/10.3390/ph16040625

Ejemplares similares